A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.
An article from
Dive Brief
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out a billion-dollar opportunity.
Published May 18, 2026
Regeneron reported negative results from a Phase 3 study in melanoma on May 15, 2026.
Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3
After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary - KFF Health News
FDA blocked melanoma drug as confusion reigned under Makary
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
Amplia takes aim at billion-dollar pancreatic cancer drug market
Merck, Kelun score with sac-TMT in endometrial cancer trial
